Literature DB >> 12140593

[HEPATITIS E IgG ANTIBODIES SEROPREVALENCE IN A PERUVIAN RISK GROUP]

Herman Vildosola, Alejandro Colichón, Milagros Barreda, Julia Piscoya, Olga Palacios.   

Abstract

We study the seroprevalence and risk factors on hepatitis E virus infection in 191 healthy subjects, which are workers of the drinking water and sewerage system of Lima city, and the main activity of them was to handle sewage at present or early past. We tested for IgG hepatitis E antibodies (anti-HEV IgG) a two recombinant antigen based enzyme immunoassay (Abbott IL USA).Anti-HEV IgG were positive in 20 subjects (10.47%) and the only one variate that we can consider related to HEV infection was rank of years worked in the company, especially when reaching 13-20 years. We conclude that hepatitis E is a endemic infection in this kind of population and the prevalence of hepatitis E infection was related to the period worked in the company.We need several prevalence studies in other kind of population in order to know the magnitude of hepatitis E infection in Peru.

Entities:  

Year:  2000        PMID: 12140593

Source DB:  PubMed          Journal:  Rev Gastroenterol Peru        ISSN: 1022-5129


  2 in total

1.  Hepatitis E Virus in People Who Use Crack-Cocaine: A Cross-Sectional Study in a Remote Region of Northern Brazil.

Authors:  Raquel Silva do Nascimento; Karen Lorena N Baia; Samara Borges de Souza; Guilherme Martins G Fontoura; Patrícia Ferreira Nunes; Luiz Fernando A Machado; Emil Kupek; Benedikt Fischer; Luísa Caricio Martins; Aldemir B Oliveira-Filho
Journal:  Viruses       Date:  2021-05-17       Impact factor: 5.048

2.  Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.

Authors:  Cesar Cabezas; Omar Trujillo; Ángel Gonzales-Vivanco; Carlos Manuel Benites Villafane; Johanna Balbuena; Alfredo Oswaldo Borda-Olivas; Magna Aurora Suarez-Jara; Flor de María Peceros; Max Carlos Ramírez-Soto
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.